1. Home
  2. PRPL vs NSRX Comparison

PRPL vs NSRX Comparison

Compare PRPL & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Purple Innovation Inc.

PRPL

Purple Innovation Inc.

HOLD

Current Price

$8.94

Market Cap

34.1M

ML Signal

HOLD

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$3.17

Market Cap

38.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRPL
NSRX
Founded
2010
2019
Country
United States
Israel
Employees
N/A
7
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1M
38.9M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
PRPL
NSRX
Price
$8.94
$3.17
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$0.65
$19.67
AVG Volume (30 Days)
173.0K
10.0K
Earning Date
04-28-2026
03-25-2026
Dividend Yield
N/A
N/A
EPS Growth
152.75
N/A
EPS
N/A
N/A
Revenue
$468,725,000.00
N/A
Revenue This Year
$8.50
N/A
Revenue Next Year
$6.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.98
52 Week High
$8.50
$9.99

Technical Indicators

Market Signals
Indicator
PRPL
NSRX
Relative Strength Index (RSI) 86.98 52.42
Support Level $0.54 $2.83
Resistance Level N/A $3.60
Average True Range (ATR) 0.62 0.18
MACD 0.40 0.01
Stochastic Oscillator 98.58 79.64

Price Performance

Historical Comparison
PRPL
NSRX

About PRPL Purple Innovation Inc.

Purple Innovation Inc designs and manufactures sleep products. Using its GelFlex Grid technology, the company designs, manufactures, and offers branded comfort sleep products, including mattresses, pillows, cushions, mattress protectors, bases, sheets, and others. It markets and sells these products through direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: